Mirae Asset Global Investments’s Autolus Therapeutics AUTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$14.4K Sell
8,971
-1,492
-14% -$2.34K ﹤0.01% 1526
2026
Q1
$14.4K Buy
10,463
+715
+7% +$1.09K ﹤0.01% 1464
2025
Q4
$19.4K Buy
9,748
+1,994
+26% +$3.06K ﹤0.01% 1537
2025
Q3
$12.6K Buy
7,754
+8
+0.1% +$16 ﹤0.01% 1547
2025
Q2
$17.7K Buy
7,746
+1,956
+34% +$3.23K ﹤0.01% 1414
2025
Q1
$9.61K Sell
5,790
-865
-13% -$1.76K ﹤0.01% 1473
2024
Q4
$15K Sell
6,655
-565
-8% -$1.91K ﹤0.01% 1460
2024
Q3
$26.2K Buy
7,220
+1,265
+21% +$5.04K ﹤0.01% 1396
2024
Q2
$19.8K Buy
+5,955
New +$25.7K ﹤0.01% 1379

Other funds holding AUTL

Mirae Asset Global Investments's AUTL Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Autolus Therapeutics (AUTL) stake by 14% in Q2 2026, selling an estimated $2.34K and leaving 8,971 shares worth $14.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1526.

Mirae Asset Global Investments first reported a position in AUTL in Q2 2024 and has held it in 9 quarters since. The position peaked at $26.2K in Q3 2024. 31 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Mirae Asset Global Investments held 8,971 shares of Autolus Therapeutics worth $14.4K as of Q2 2026.
  • Mirae Asset Global Investments sold 1,492 Autolus Therapeutics shares in Q2 2026, an estimated $2.34K.
  • Autolus Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1526 holding.
  • Mirae Asset Global Investments first reported a position in Autolus Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Mirae Asset Global Investments's Autolus Therapeutics position peaked at $26.2K in Q3 2024.
  • 31 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.